Editorial: inhibitors of cdk family: new perspective and rationale for drug combination in preclinical models of solid tumors

HIGHLIGHTS

SUMMARY

CDK, solid tumors, pre-clinical, combination, Rb Editorial on the Research Topic Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical model of solid tumors COPYRIGHT Frontiers in Oncology The CDK family includes enzymes involved in cell cycle progression and transcriptional regulation. Although various CDKs and cyclins have been identified, specific CDK-cyclin complexes are mandatory to control cell cycle progression, i.e., through the G1, S, G2, and M phases. The activity of CDK4/6 is mainly addressed to the tumor suppressor protein retinoblastoma (Rb) that causes the inactivation . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.